Cart
sales@molnova.com
Veliparib dihydrochloride
CAS No. 912445-05-7
Veliparib dihydrochloride( ABT-888 dihydrochloride | ABT888 dihydrochloride | ABT 888 dihydrochloride )
Catalog No. M16549 CAS No. 912445-05-7
Veliparib (ABT-888) is a potent, BBB penetrant, and orally active PARP inhibitor with IC50 of 5.2 and 2.9 nM for PARP-1 and PARP-2, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 38 | In Stock |
|
| 25MG | 67 | In Stock |
|
| 50MG | 110 | In Stock |
|
| 100MG | 177 | In Stock |
|
| 200MG | 288 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVeliparib dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionVeliparib (ABT-888) is a potent, BBB penetrant, and orally active PARP inhibitor with IC50 of 5.2 and 2.9 nM for PARP-1 and PARP-2, respectively.
-
DescriptionVeliparib (ABT-888) is a potent, BBB penetrant, and orally active PARP inhibitor with IC50 of 5.2 and 2.9 nM for PARP-1 and PARP-2, respectively; displays no activity against SIRT2 and selective biochemical profile in a panel of 74 receptor-binding assays; strongly potentiates temozolomide in the B16F10 s.c. murine melanoma model, also potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. Breast Cancer Phase 3 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsABT-888 dihydrochloride | ABT888 dihydrochloride | ABT 888 dihydrochloride
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP1|PARP2
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number912445-05-7
-
Formula Weight317.2142
-
Molecular FormulaC13H18Cl2N4O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 3.2 mg/mL
-
SMILESC[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl
-
Chemical Name1H-Benzimidazole-7-carboxamide, 2-[(2R)-2-methyl-2-pyrrolidinyl]-, hydrochloride (1:2)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Donawho CK, et al. Clin Cancer Res. 2007 May 1;13(9):2728-37.
2. Albert JM, et al. Clin Cancer Res. 2007 May 15;13(10):3033-42.
3. Liu X, et al. Mol Cancer Res. 2008 Oct;6(10):1621-9.
4. Palma JP, et al. Anticancer Res. 2008 Sep-Oct;28(5A):2625-35.
molnova catalog
related products
-
AZD5305
AZD5305 is a potent, selective and oral active PARP inhibitor.
-
AZD-9574
AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies.
-
UNBS-5162
UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
